Caring Brands Eyes Nasdaq Listing, $4M Public Offering for Wellness Products

TL;DR

**CABR's Nasdaq bid and $4M raise is a high-risk bet on a product relaunch after a prior flop; proceed with extreme caution.**

AI Summary

Caring Brands, Inc. (CABR) is a wellness consumer products company offering OTC and cosmetic products, with a primary focus on Photocil, a narrow-band UV filter for vitiligo and psoriasis. The company is conducting a public offering of 1,000,000 shares of common stock at an assumed price of $4.00 per share, aiming to raise $4,000,000 in gross proceeds and $3,680,000 after underwriting discounts and expenses. Photocil was briefly launched in the U.S. from December 2022 to February 2023 but was removed due to insufficient sales, with a relaunch targeted for 2026. The product is currently marketed in India under local cosmetic regulations. The global phototherapy treatment market, relevant to Photocil, is projected to grow from approximately $1.9 billion in 2023 to $3.23 billion by 2033, at a CAGR of 5.2%. CABR has applied to list its common stock on The Nasdaq Capital Market under the symbol 'CABR', expecting to cease trading on OTCQB (CBRA) upon approval. The filing also registers 2,610,000 shares for resale by selling stockholders, including 2,110,000 warrant shares and 500,000 shares held by Jordan Fried.

Why It Matters

This S-1/A filing signals Caring Brands' intent to uplist to Nasdaq, a move that could significantly increase visibility and liquidity for investors, potentially attracting a broader institutional base. The $4 million public offering provides capital for the company's operations and the planned 2026 U.S. relaunch of Photocil, a key product in the growing phototherapy market. However, the prior failure of Photocil in the U.S. due to 'insufficient sales' highlights significant competitive and marketing challenges, making the success of the relaunch critical for future revenue and investor confidence. Employees and customers could benefit from increased investment in product development and marketing if the offering and Nasdaq listing are successful.

Risk Assessment

Risk Level: high — The company explicitly states, 'An investment in our securities is highly speculative, involves a high degree of risk and should be considered only by persons who can afford the loss of their entire investment.' This is further evidenced by Photocil's removal from the U.S. market from December 2022 to February 2023 due to 'insufficient sales,' indicating significant market acceptance challenges despite a projected $3.23 billion global phototherapy market by 2033.

Analyst Insight

Investors should carefully evaluate Caring Brands' ability to execute a successful U.S. relaunch of Photocil in 2026, given its prior market failure. Consider the high speculative nature and potential for complete loss of investment, as explicitly stated in the filing. Monitor the Nasdaq listing approval and the company's strategic plans for sales and marketing before committing capital.

Executive Compensation

Key Numbers

• $4.00 — Assumed Public Offering Price Per Share (Basis for calculating gross proceeds of the offering)
• $4,000,000 — Total Public Offering Gross Proceeds (Amount expected to be raised from the sale of 1,000,000 shares)
• $3,680,000 — Proceeds to Company Before Expenses (Net proceeds after $320,000 in underwriting discounts and commissions)
• 1,000,000 — Shares Offered in Public Offering (Number of common stock shares being sold to the public)
• 2,610,000 — Shares Registered for Resale by Selling Stockholders (Includes 2,110,000 warrant shares and 500,000 shares held by Jordan Fried)
• $1.9 billion — Global Phototherapy Treatment Market (2023) (Estimated market size in 2023, according to Future Market Insights)
• $3.23 billion — Projected Global Phototherapy Treatment Market (2033) (Expected market size by 2033, growing at a 5.2% CAGR)
• 5.2% — CAGR of Global Phototherapy Treatment Market (Projected compound annual growth rate from 2023 to 2033)
• 8% — Underwriting Discounts and Commissions (Percentage of gross proceeds paid to underwriters ($0.32 per share))
• 3% — Warrants to Underwriters (Percentage of shares offered to be issued as warrants to the representative of the underwriters)

Key Players & Entities

• Caring Brands, Inc. (company) — Registrant and issuer of common stock
• Glynn Wilson (person) — Chief Executive Officer of Caring Brands, Inc.
• Sichenzia Ross Ference Carmel LLP (company) — Legal counsel for the registrant
• Lucosky Brookman LLP (company) — Legal counsel for the registrant
• D. BORAL CAPITAL (company) — Sole Underwriter for the public offering
• Jordan Fried (person) — Selling shareholder holding 500,000 shares of Common Stock
• U.S. Securities and Exchange Commission (regulator) — Regulatory body for the S-1/A filing
• The Nasdaq Capital Market (company) — Targeted stock exchange for listing
• OTCQB (company) — Current trading market for common stock
• Future Market Insights (company) — Source of market data for phototherapy treatment market

FAQ

Risk Factors

• Dependence on Photocil Product [high — operational]: The company's success is heavily reliant on Photocil, a single product. The prior U.S. launch from December 2022 to February 2023 failed due to insufficient sales, indicating significant market acceptance risk. A relaunch is planned for 2026, but there is no guarantee of success.
• Navigating International Regulations [medium — regulatory]: Photocil is currently marketed in India under local cosmetic regulations. Changes in these regulations or the inability to comply with evolving international cosmetic and pharmaceutical standards could materially impact the company's ability to sell its products globally.
• Limited Operating History and Profitability [high — financial]: The company has a limited operating history and has not demonstrated consistent profitability. The S-1 filing does not provide detailed historical financial statements, making it difficult to assess its financial stability and future earning potential.
• Competition in the Wellness Market [medium — market]: The wellness consumer products market is competitive. While Photocil targets a niche, the broader phototherapy treatment market faces competition from established players and alternative treatments, potentially limiting market share and pricing power.
• Reliance on Public Offering Proceeds [high — financial]: The company is seeking to raise $4,000,000 in gross proceeds from this offering. If the offering is unsuccessful or raises less than anticipated, it could significantly hinder the company's ability to fund its operations, product development, and relaunch efforts.
• Relaunch Strategy Uncertainty [high — operational]: The planned relaunch of Photocil in the U.S. in 2026 is a critical future event. The failure of the initial launch suggests potential challenges in market penetration, marketing strategy, and consumer adoption, creating uncertainty around the success of the relaunch.

Industry Context

Caring Brands operates in the wellness consumer products sector, with a specific focus on phototherapy treatments for dermatological conditions like vitiligo and psoriasis. The global phototherapy treatment market is projected to grow from $1.9 billion in 2023 to $3.23 billion by 2033, at a CAGR of 5.2%. This indicates a growing market, but the company faces competition from established players and alternative treatments.

Regulatory Implications

The company must navigate varying international cosmetic and pharmaceutical regulations, particularly for its primary product, Photocil. The prior U.S. market withdrawal due to insufficient sales highlights the challenges in meeting market demands and regulatory compliance. Future success depends on adhering to evolving global standards.

What Investors Should Do

1. Evaluate the viability of the Photocil relaunch strategy.
2. Assess the company's ability to navigate international regulatory landscapes.
3. Analyze the financial health and cash burn rate.
4. Consider the dilution impact from selling stockholders and warrants.

Key Dates

• 2022-12-01: Initial U.S. Launch of Photocil — Marked the company's first attempt to penetrate the U.S. market with its primary product.
• 2023-02-01: U.S. Photocil Launch Withdrawal — Indicated insufficient sales and highlighted market acceptance challenges, leading to a strategic pause.
• 2026-01-01: Targeted Photocil U.S. Relaunch — Represents a key future event for the company's revenue generation and market strategy.

Glossary

Photocil

A narrow-band UV filter product developed by Caring Brands, Inc., intended for use by individuals with vitiligo and psoriasis. (It is the company's primary product and the main focus of its business strategy and revenue generation.)

S-1/A

An amendment to a registration statement filed with the U.S. Securities and Exchange Commission (SEC) for a public offering of securities. (This filing provides detailed information about the company's business, financials, risks, and the proposed stock offering.)

OTC Market

Over-the-counter market, a decentralized market where securities are traded directly between parties without a central exchange. (Caring Brands is currently trading on the OTCQB market (CBRA) and intends to move to the Nasdaq Capital Market.)

Nasdaq Capital Market

A tier of the Nasdaq stock market that lists smaller companies and has specific listing requirements. (The company is seeking to list its common stock on this exchange, which could improve liquidity and visibility.)

Selling Stockholders

Existing shareholders who are registering their shares for resale to the public. (A significant number of shares (2,610,000) are being registered for resale by these stockholders, including warrant shares and shares held by Jordan Fried.)

Warrant

A security that gives the holder the right, but not the obligation, to purchase a company's stock at a specific price on or before a certain date. (2,110,000 shares are registered for resale by selling stockholders who hold warrants, indicating potential future dilution or capital infusion.)

CAGR

Compound Annual Growth Rate, a measure of the average annual growth of an investment over a specified period of time longer than one year. (Used to project the growth of the global phototherapy treatment market, indicating a moderate growth outlook for the industry.)

Year-Over-Year Comparison

This S-1/A filing represents a significant step for Caring Brands, Inc. as it seeks to transition from the OTCQB market to the Nasdaq Capital Market and raise capital through a public offering. Unlike previous filings that might have focused on initial product development or market entry, this document details a proposed offering of 1,000,000 shares to raise $4,000,000 in gross proceeds. It also highlights a critical operational challenge: the prior failure of Photocil's U.S. launch and the planned 2026 relaunch, indicating a shift in strategy and a focus on future market penetration rather than current established revenue streams.

Key Financial Figures

• $0.001 — 0,000 shares of common stock, par value $0.001 (the “Common Stock”) throug
• $4.50 — ce of our common stock on the OTCQB was $4.50 per share. The final public offering pr
• $4.00 — fering price per share is assumed to be $4.00 per share. The table above assumes no e
• $0.32 — proceeds of the offering per share (or $0.32 per share). We have agreed to pay a non
• $0.04 — of the gross proceeds of this offering ($0.04 per share) payable to the representativ
• $1.9billion — market is projected to rise from ~ USD $1.9billion in 2023 to ~ USD $3.23billion by 2033,
• $3.23billion — from ~ USD $1.9billion in 2023 to ~ USD $3.23billion by 2033, at a CAGR of around 5.2% durin
• $34 billion — psoriasis treatment market was worth ~ $34 billion globally in the 12 months ending June 2
• $54 — lobal market is expected to reach ~ USD $54-67 billion by 2030. Estimates from a re

Filing Documents

• forms-1a.htm (S-1/A) — 2177KB
• ex5-1.htm (EX-5.1) — 14KB
• ex10-23.htm (EX-10.23) — 17KB
• ex23-1.htm (EX-23.1) — 5KB
• formdrs_001.jpg (GRAPHIC) — 1KB
• fin_001.jpg (GRAPHIC) — 1KB
• fin_002.jpg (GRAPHIC) — 1KB
• fin_003.jpg (GRAPHIC) — 1KB
• ex23-1_001.jpg (GRAPHIC) — 11KB
• ex5-1_001.jpg (GRAPHIC) — 17KB
• audit_001.jpg (GRAPHIC) — 32KB
• 0001493152-25-014256.txt ( ) — 2306KB

USE OF PROCEEDS

USE OF PROCEEDS 26 DIVIDEND POLICY 26 Consolidated Financial Statements 28 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 31

BUSINESS

BUSINESS 36 MANAGEMENT 47 EXECUTIVE AND DIRECTOR COMPENSATION 52 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 53

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 57

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 58 SHARES ELIGIBLE FOR FUTURE SALE 61 CERTAIN INCOME TAX CONSIDERATIONS 63

UNDERWRITING

UNDERWRITING 66 LEGAL MATTERS 71 EXPERTS 71 WHERE YOU CAN FIND MORE INFORMATION 71 INDEX TO FINANCIAL STATEMENTS F-1 Please read this prospectus carefully. It describes our business, our financial condition, and our results of operations. We have prepared this prospectus so that you will have the information necessary to make an informed investment decision. You should rely only on the information contained in this prospectus or in any related free writing prospectus. We have not, and the underwriters have not, authorized anyone to provide you with information different from that contained in this prospectus or in any related free writing prospectus. Neither we, the selling stockholders nor any of the underwriters have authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses we have prepared. Neither we, the selling stockholders nor any of the underwriters take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of its date, regardless of the time of delivery of this prospectus or of any sale of our common stock. For investors outside the United States: Neither we, the selling stockholders nor any of the underwriters have done anything that would permit this offering or the possession or distribution of this prospectus in any jurisdiction where action for those purposes is required, other than in the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of our common stock and the distribution of this prospectus outside of the United

View Full Filing

View this S-1/A filing on SEC EDGAR